Stockscreener 앱 받기
3.94
4.37%
-0.18
시간 외 거래:
3.99
0.05
+1.27%
Tscan Therapeutics Inc 주식(TCRX)의 최신 뉴스
LMR Partners LLP Trims Stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Tscan therapeutics sees $4,113 stock purchase by Lynx1 capital - Investing.com India
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? - MSN
Lynx1 Capital Management LP Increases Stake in TScan Therapeutics Inc - GuruFocus.com
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
FY2024 Earnings Estimate for TCRX Issued By Lifesci Capital - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Wedbush Research Analysts Boost Earnings Estimates for TCRX - MarketBeat
TScan Therapeutics Inc (TCRX) Quarterly 10-Q Report - Quartzy
Wedbush Has Positive Forecast for TCRX FY2028 Earnings - MarketBeat
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts By Investing.com - Investing.com Nigeria
TScan Therapeutics' SWOT analysis: biotech stock poised for key catalysts - Investing.com India
TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX) - Defense World
TScan Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tscan Therapeutics earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
New Blood Cancer Treatment Shows Continued Response - Streetwise Reports
Tscan Therapeutics Inc’s (TCRX) 7.56% Increase Justifies A Second Look - Stocks Register
TScan Therapeutics' (TCRX) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews - Benzinga
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet? - Simply Wall St
TScan Therapeutics' SWOT analysis: innovative therapy stock faces pivotal year - Investing.com Australia
TScan Therapeutics Announces Upcoming Oral Presentation of - GlobeNewswire
TScan's Blood Cancer Trial Shows Zero Relapses: Breakthrough Phase 1 Results | TCRX Stock News - StockTitan
Waltham cancer biotech adds to real estate footprint - The Business Journals
TScan Therapeutics (NASDAQ:TCRX) Enters Second Amendment for Lease Agreement to Expand Operations at Winter Street FacilityOn October 28, 2024, TScan Therapeutics, Inc. finalized a second amendment to its lease agreement with PPF OFF 828-83 - Defense World
TScan expands Waltham facility with additional lease - Investing.com India
TScan expands Waltham facility with additional lease By Investing.com - Investing.com UK
Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
The Manufacturers Life Insurance Company Invests $90,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Where are the Opportunities in (TCRX) - Stock Traders Daily
BTIG Initiates Coverage of TScan Therapeutics (TCRX) with Buy Recommendation - MSN
Bank of Montreal Can Acquires Shares of 120,454 TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Bank of Montreal Can Invests $749,000 in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
(TCRX) On The My Stocks Page - Stock Traders Daily
TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Position Lifted by Marshall Wace LLP - MarketBeat
American Century Companies Inc. Increases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
TCRXTScan Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
TScan Therapeutics Announces Upcoming Presentations at the - GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - StockTitan
Reviewing TScan Therapeutics (NASDAQ:TCRX) and Sorrento Therapeutics (OTCMKTS:SRNEQ) - Defense World
Tscan Therapeutics Inc [TCRX] Stock bought by Insider Klencke Barbara for $26450.0 - Knox Daily
Was there any good news for Tscan Therapeutics Inc (TCRX) stock in the last session? - US Post News
Market Momentum Report: Tscan Therapeutics Inc (TCRX)’s Negative Close at 4.98 - The Dwinnex
TScan Therapeutics's SWOT analysis: biotech stock faces pivotal year - Investing.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Growth in Short Interest - MarketBeat
92,832 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Bought by Troluce Capital Advisors LLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke Acquires 5,000 Shares - Defense World
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com South Africa
0.93%
3.55%
자본화:
|
볼륨(24시간):